When Air and Surface Purification is a Must,
Our Healthcare Solution Does Not Compromise
Today’s healthcare environments deserve hospital-grade solutions. CASPR Medik™ is clinically proven to reduce pathogens to up to 99.96% throughout your hospital, clinic and other healthcare facilities.
Using HEPA filters, our products are designed to be seamlessly installed in HVAC ducts, providing continuous disinfection in any space. And, our products can be used safely in occupied spaces, with no need to remove staff, patients or to seal rooms.
The Hospital-Grade Air and Surface Purifier
CASPR Medik™ is our medical-grade solution that provides constant, stable levels of hydrogen peroxide to targeted areas. Units are inserted into existing HVAC ducts where they will reacts with your ambient air to create low levels of hydrogen peroxide (between .02 and .03 ppm). These molecules then circulate the air, land on all surfaces, and actively reduce micro-burdens as soon as contamination occurs. CASPR’s continuous nature allows us to not only reduce the Colony Forming Units (CFUs) but it keeps them down by preventing them from multiplying in-between episodic cleaning and disinfecting.
That’s Truly No-Touch
CASPR Medik allows you to protect your patients and staff from the moment they step foot into your facility. CASPR’s continuous air and surface pathogen reduction technology offers no touch, facility-wide, enhanced disinfection. CASPR technology used in occupied spaces has helped hospitals improve their throughput times and reduce employee absenteeism by over 40%. To learn more about our technology, review the latest whitepaper.
|CASPR Medik||Ultraviolet Light||Hydrogen Misters|
|Proven effective against a broad spectrum of clinically relevant pathogens||Yes||Yes||Yes|
|Continuous pathogen reduction||Yes||No||No|
|No disruption or delayed access to clinical areas||Yes||No||No|
|Continuously eliminates odors||Yes||No||No|
|No operator required (true "No-Touch")||Yes||No||No|
|No capital expenditure||Yes||No||No|
|No sensitive use parameters||Yes||No||No|
CASPR Medik Proven Results
CASPR has been proven effective against relevant pathogens in both independent laboratory settings and hospital trials. In our latest studies, we were able to reduce employee absenteeism by 42% year-over-year at one hospital and reduce HAIs by 53% at another hospital.
- Clostridium difficile
- Aspergillus Niger
To request lab and hospital results or to obtain a copy of our peer-reviewed and authored ICHE publication, contact us by clicking the link below.
“You couldn’t ask for anything better. CASPR is continuous disinfection. You don’t have to have the staff involved because it is no-touch. It is completely automated.” – Lori Townsend, MSN, CIC, CPHQ
“We were interviewing companies that would be an adjunct to our Infection Control program and this company stood out for many reason. Their technology was hands down the best in the fact that it is non-invasive and the particles are able to get to areas that no other technology could. This technology has improved our patient safety and facility. Our culture results have shown a dramatic decrease in the amount of bioburden and that has impacted our surgical site infections and we have had less employees getting sick.” – Elizabeth Hardy, R.N., B.S.N.
“CASPR gave me the confidence to start seeing patients in my office, again. It is good to know that our air and surfaces are continually being treated. And, knowing that my patients are as safe as they can be gives me peace of mind.” – Suzanne Slonim, MD
CASPR Medik Overview
Third Party Research
Vital Signs: Preventing Antibiotic-Resistant Infections in Hospitals — United States, 2014
Lindsey M. Weiner, MPH; Scott K. Fridkin, MD; Zuleika Aponte-Torres, MPH; Lacey Avery, MA1; Nicole Coffin, MA; Margaret A. Dudeck, MPH; Jonathan R. Edwards, MStat; John A. Jernigan, MD; Rebecca Konnor, MPH; Minn M. Soe, MBBS, MPH; Kelly Peterson; L. Clifford McDonald, MD
Enhanced terminal room disinfection and acquisition and infection caused by multidrug-resistant organisms and Clostridium difficile (the Benefits of Enhanced Terminal Room Disinfection study)
Dr Deverick J Anderson, MD, Luke F Chen, MBBS, Prof David J Weber, MD, Rebekah W Moehring, MD, Sarah S Lewis, MD, Patricia F Triplett, et al.